modelJ02AC04
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Posaconazole | |
| ATC code: | J02AC04 | route: | oral |
| compartments: | 1 | |
| dosage: | 400 | mg |
| volume of distribution: | 236 | L |
| clearance: | 7.5 | L/h |
| other parameters in model implementation | ||
Posaconazole is a triazole antifungal agent approved for the prevention and treatment of invasive fungal infections caused by Aspergillus and Candida species in immunocompromised patients. It is used both for prophylaxis in patients at high risk for fungal infections and for treatment of ongoing invasive infections. Approved by FDA and widely used in clinical practice.
Pharmacokinetics
Healthy adult volunteers (median age 26, range 18–45), single-dose pharmacokinetics of oral posaconazole suspension following 400 mg dose in the fed state.
References
Chen, L, et al., & Brüggemann, RJM (2020). Pharmacokinetics and Pharmacodynamics of Posaconazole. Drugs 80(7) 671–695. DOI:10.1007/s40265-020-01306-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/32323222
Selby, PR, et al., & Roberts, JA (2024). Population pharmacokinetics of posaconazole in allogeneic haematopoietic stem cell transplant patients. The Journal of antimicrobial chemotherapy 79(3) 567–577. DOI:10.1093/jac/dkae006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38217845
Ding, Q, et al., & Pei, Q (2022). A Review of Population Pharmacokinetic Models of Posaconazole. Drug design, development and therapy 16 3691–3709. DOI:10.2147/DDDT.S384637 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36277600
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)